ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global APOL1 Mediated Kidney Disease Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-9Y10149
Home | Market Reports | Health| Health Conditions
Global APOL1 Mediated Kidney Disease Market Insights Forecast to 2028
BUY CHAPTERS

Global APOL1 Mediated Kidney Disease Market Research Report 2025

Code: QYRE-Auto-9Y10149
Report
July 2025
Pages:75
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Vertex Pharmaceuticals
Ionis Pharmaceuticals
ChemoCentryx Inc
GlaxoSmithKline PLC
Novartis
Teva Pharmaceuticals
Travere Therapeutics
ZyVersa Therapeutics

APOL1 Mediated Kidney Disease Market Size

The global market for APOL1 Mediated Kidney Disease was valued at US$ 905 million in the year 2024 and is projected to reach a revised size of US$ 1354 million by 2031, growing at a CAGR of 6.0% during the forecast period.

APOL1 Mediated Kidney Disease Market

APOL1 Mediated Kidney Disease Market

APOL1 gene is a member of APOL gene family, which plays an important role in innate immunity, which is our body’s built-in defense system to fight threats. Some variations in APOL1 gene cause damage to parts within the kidney. Damage to parts that filter blood can lead to severe kidney disease or ultimately kidney failure. An example of such an indication is focal segmental glomerulosclerosis (FSGS), which is a type of kidney disease that can be caused by APOL1 gene variations.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for APOL1 Mediated Kidney Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding APOL1 Mediated Kidney Disease.
The APOL1 Mediated Kidney Disease market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global APOL1 Mediated Kidney Disease market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the APOL1 Mediated Kidney Disease companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of APOL1 Mediated Kidney Disease Market Report

Report Metric Details
Report Name APOL1 Mediated Kidney Disease Market
Accounted market size in year US$ 905 million
Forecasted market size in 2031 US$ 1354 million
CAGR 6.0%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Vertex Pharmaceuticals, Ionis Pharmaceuticals, Travere Therapeutics, ChemoCentryx, ZyVersa Therapeutics, GlaxoSmithKline, Novartis, Teva Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of APOL1 Mediated Kidney Disease company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is APOL1 Mediated Kidney Disease Market growing?

Ans: The APOL1 Mediated Kidney Disease Market witnessing a CAGR of 6.0% during the forecast period 2025-2031.

What is the APOL1 Mediated Kidney Disease Market size in 2031?

Ans: The APOL1 Mediated Kidney Disease Market size in 2031 will be US$ 1354 million.

Who are the main players in the APOL1 Mediated Kidney Disease Market report?

Ans: The main players in the APOL1 Mediated Kidney Disease Market are Vertex Pharmaceuticals, Ionis Pharmaceuticals, Travere Therapeutics, ChemoCentryx, ZyVersa Therapeutics, GlaxoSmithKline, Novartis, Teva Pharmaceuticals

What are the Application segmentation covered in the APOL1 Mediated Kidney Disease Market report?

Ans: The Applications covered in the APOL1 Mediated Kidney Disease Market report are Chronic Kidney Disease, End Stage Kidney Disease

What are the Type segmentation covered in the APOL1 Mediated Kidney Disease Market report?

Ans: The Types covered in the APOL1 Mediated Kidney Disease Market report are Small Molecule, Gene Modification, Nucleic Acid Therapies, Others

Recommended Reports

Kidney Disease Markets

Genetic & Autoimmune

Renal and Related Therapies

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global APOL1 Mediated Kidney Disease Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Small Molecule
1.2.3 Gene Modification
1.2.4 Nucleic Acid Therapies
1.2.5 Others
1.3 Market by Application
1.3.1 Global APOL1 Mediated Kidney Disease Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Chronic Kidney Disease
1.3.3 End Stage Kidney Disease
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global APOL1 Mediated Kidney Disease Market Perspective (2020-2031)
2.2 Global APOL1 Mediated Kidney Disease Growth Trends by Region
2.2.1 Global APOL1 Mediated Kidney Disease Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 APOL1 Mediated Kidney Disease Historic Market Size by Region (2020-2025)
2.2.3 APOL1 Mediated Kidney Disease Forecasted Market Size by Region (2026-2031)
2.3 APOL1 Mediated Kidney Disease Market Dynamics
2.3.1 APOL1 Mediated Kidney Disease Industry Trends
2.3.2 APOL1 Mediated Kidney Disease Market Drivers
2.3.3 APOL1 Mediated Kidney Disease Market Challenges
2.3.4 APOL1 Mediated Kidney Disease Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top APOL1 Mediated Kidney Disease Players by Revenue
3.1.1 Global Top APOL1 Mediated Kidney Disease Players by Revenue (2020-2025)
3.1.2 Global APOL1 Mediated Kidney Disease Revenue Market Share by Players (2020-2025)
3.2 Global APOL1 Mediated Kidney Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by APOL1 Mediated Kidney Disease Revenue
3.4 Global APOL1 Mediated Kidney Disease Market Concentration Ratio
3.4.1 Global APOL1 Mediated Kidney Disease Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by APOL1 Mediated Kidney Disease Revenue in 2024
3.5 Global Key Players of APOL1 Mediated Kidney Disease Head office and Area Served
3.6 Global Key Players of APOL1 Mediated Kidney Disease, Product and Application
3.7 Global Key Players of APOL1 Mediated Kidney Disease, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 APOL1 Mediated Kidney Disease Breakdown Data by Type
4.1 Global APOL1 Mediated Kidney Disease Historic Market Size by Type (2020-2025)
4.2 Global APOL1 Mediated Kidney Disease Forecasted Market Size by Type (2026-2031)
5 APOL1 Mediated Kidney Disease Breakdown Data by Application
5.1 Global APOL1 Mediated Kidney Disease Historic Market Size by Application (2020-2025)
5.2 Global APOL1 Mediated Kidney Disease Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America APOL1 Mediated Kidney Disease Market Size (2020-2031)
6.2 North America APOL1 Mediated Kidney Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America APOL1 Mediated Kidney Disease Market Size by Country (2020-2025)
6.4 North America APOL1 Mediated Kidney Disease Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe APOL1 Mediated Kidney Disease Market Size (2020-2031)
7.2 Europe APOL1 Mediated Kidney Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe APOL1 Mediated Kidney Disease Market Size by Country (2020-2025)
7.4 Europe APOL1 Mediated Kidney Disease Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific APOL1 Mediated Kidney Disease Market Size (2020-2031)
8.2 Asia-Pacific APOL1 Mediated Kidney Disease Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Region (2020-2025)
8.4 Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America APOL1 Mediated Kidney Disease Market Size (2020-2031)
9.2 Latin America APOL1 Mediated Kidney Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America APOL1 Mediated Kidney Disease Market Size by Country (2020-2025)
9.4 Latin America APOL1 Mediated Kidney Disease Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa APOL1 Mediated Kidney Disease Market Size (2020-2031)
10.2 Middle East & Africa APOL1 Mediated Kidney Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Country (2020-2025)
10.4 Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Vertex Pharmaceuticals
11.1.1 Vertex Pharmaceuticals Company Details
11.1.2 Vertex Pharmaceuticals Business Overview
11.1.3 Vertex Pharmaceuticals APOL1 Mediated Kidney Disease Introduction
11.1.4 Vertex Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2020-2025)
11.1.5 Vertex Pharmaceuticals Recent Development
11.2 Ionis Pharmaceuticals
11.2.1 Ionis Pharmaceuticals Company Details
11.2.2 Ionis Pharmaceuticals Business Overview
11.2.3 Ionis Pharmaceuticals APOL1 Mediated Kidney Disease Introduction
11.2.4 Ionis Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2020-2025)
11.2.5 Ionis Pharmaceuticals Recent Development
11.3 Travere Therapeutics
11.3.1 Travere Therapeutics Company Details
11.3.2 Travere Therapeutics Business Overview
11.3.3 Travere Therapeutics APOL1 Mediated Kidney Disease Introduction
11.3.4 Travere Therapeutics Revenue in APOL1 Mediated Kidney Disease Business (2020-2025)
11.3.5 Travere Therapeutics Recent Development
11.4 ChemoCentryx
11.4.1 ChemoCentryx Company Details
11.4.2 ChemoCentryx Business Overview
11.4.3 ChemoCentryx APOL1 Mediated Kidney Disease Introduction
11.4.4 ChemoCentryx Revenue in APOL1 Mediated Kidney Disease Business (2020-2025)
11.4.5 ChemoCentryx Recent Development
11.5 ZyVersa Therapeutics
11.5.1 ZyVersa Therapeutics Company Details
11.5.2 ZyVersa Therapeutics Business Overview
11.5.3 ZyVersa Therapeutics APOL1 Mediated Kidney Disease Introduction
11.5.4 ZyVersa Therapeutics Revenue in APOL1 Mediated Kidney Disease Business (2020-2025)
11.5.5 ZyVersa Therapeutics Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Details
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline APOL1 Mediated Kidney Disease Introduction
11.6.4 GlaxoSmithKline Revenue in APOL1 Mediated Kidney Disease Business (2020-2025)
11.6.5 GlaxoSmithKline Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis APOL1 Mediated Kidney Disease Introduction
11.7.4 Novartis Revenue in APOL1 Mediated Kidney Disease Business (2020-2025)
11.7.5 Novartis Recent Development
11.8 Teva Pharmaceuticals
11.8.1 Teva Pharmaceuticals Company Details
11.8.2 Teva Pharmaceuticals Business Overview
11.8.3 Teva Pharmaceuticals APOL1 Mediated Kidney Disease Introduction
11.8.4 Teva Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2020-2025)
11.8.5 Teva Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Vertex Pharmaceuticals
Ionis Pharmaceuticals
ChemoCentryx Inc
GlaxoSmithKline PLC
Novartis
Teva Pharmaceuticals
Travere Therapeutics
ZyVersa Therapeutics
List of Tables
 Table 1. Global APOL1 Mediated Kidney Disease Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Small Molecule
 Table 3. Key Players of Gene Modification
 Table 4. Key Players of Nucleic Acid Therapies
 Table 5. Key Players of Others
 Table 6. Global APOL1 Mediated Kidney Disease Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global APOL1 Mediated Kidney Disease Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global APOL1 Mediated Kidney Disease Market Size by Region (2020-2025) & (US$ Million)
 Table 9. Global APOL1 Mediated Kidney Disease Market Share by Region (2020-2025)
 Table 10. Global APOL1 Mediated Kidney Disease Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 11. Global APOL1 Mediated Kidney Disease Market Share by Region (2026-2031)
 Table 12. APOL1 Mediated Kidney Disease Market Trends
 Table 13. APOL1 Mediated Kidney Disease Market Drivers
 Table 14. APOL1 Mediated Kidney Disease Market Challenges
 Table 15. APOL1 Mediated Kidney Disease Market Restraints
 Table 16. Global APOL1 Mediated Kidney Disease Revenue by Players (2020-2025) & (US$ Million)
 Table 17. Global APOL1 Mediated Kidney Disease Market Share by Players (2020-2025)
 Table 18. Global Top APOL1 Mediated Kidney Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in APOL1 Mediated Kidney Disease as of 2024)
 Table 19. Ranking of Global Top APOL1 Mediated Kidney Disease Companies by Revenue (US$ Million) in 2024
 Table 20. Global 5 Largest Players Market Share by APOL1 Mediated Kidney Disease Revenue (CR5 and HHI) & (2020-2025)
 Table 21. Global Key Players of APOL1 Mediated Kidney Disease, Headquarters and Area Served
 Table 22. Global Key Players of APOL1 Mediated Kidney Disease, Product and Application
 Table 23. Global Key Players of APOL1 Mediated Kidney Disease, Date of Enter into This Industry
 Table 24. Mergers & Acquisitions, Expansion Plans
 Table 25. Global APOL1 Mediated Kidney Disease Market Size by Type (2020-2025) & (US$ Million)
 Table 26. Global APOL1 Mediated Kidney Disease Revenue Market Share by Type (2020-2025)
 Table 27. Global APOL1 Mediated Kidney Disease Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 28. Global APOL1 Mediated Kidney Disease Revenue Market Share by Type (2026-2031)
 Table 29. Global APOL1 Mediated Kidney Disease Market Size by Application (2020-2025) & (US$ Million)
 Table 30. Global APOL1 Mediated Kidney Disease Revenue Market Share by Application (2020-2025)
 Table 31. Global APOL1 Mediated Kidney Disease Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 32. Global APOL1 Mediated Kidney Disease Revenue Market Share by Application (2026-2031)
 Table 33. North America APOL1 Mediated Kidney Disease Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 34. North America APOL1 Mediated Kidney Disease Market Size by Country (2020-2025) & (US$ Million)
 Table 35. North America APOL1 Mediated Kidney Disease Market Size by Country (2026-2031) & (US$ Million)
 Table 36. Europe APOL1 Mediated Kidney Disease Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 37. Europe APOL1 Mediated Kidney Disease Market Size by Country (2020-2025) & (US$ Million)
 Table 38. Europe APOL1 Mediated Kidney Disease Market Size by Country (2026-2031) & (US$ Million)
 Table 39. Asia-Pacific APOL1 Mediated Kidney Disease Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 40. Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Region (2020-2025) & (US$ Million)
 Table 41. Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Region (2026-2031) & (US$ Million)
 Table 42. Latin America APOL1 Mediated Kidney Disease Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 43. Latin America APOL1 Mediated Kidney Disease Market Size by Country (2020-2025) & (US$ Million)
 Table 44. Latin America APOL1 Mediated Kidney Disease Market Size by Country (2026-2031) & (US$ Million)
 Table 45. Middle East & Africa APOL1 Mediated Kidney Disease Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 46. Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Country (2020-2025) & (US$ Million)
 Table 47. Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Country (2026-2031) & (US$ Million)
 Table 48. Vertex Pharmaceuticals Company Details
 Table 49. Vertex Pharmaceuticals Business Overview
 Table 50. Vertex Pharmaceuticals APOL1 Mediated Kidney Disease Product
 Table 51. Vertex Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2020-2025) & (US$ Million)
 Table 52. Vertex Pharmaceuticals Recent Development
 Table 53. Ionis Pharmaceuticals Company Details
 Table 54. Ionis Pharmaceuticals Business Overview
 Table 55. Ionis Pharmaceuticals APOL1 Mediated Kidney Disease Product
 Table 56. Ionis Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2020-2025) & (US$ Million)
 Table 57. Ionis Pharmaceuticals Recent Development
 Table 58. Travere Therapeutics Company Details
 Table 59. Travere Therapeutics Business Overview
 Table 60. Travere Therapeutics APOL1 Mediated Kidney Disease Product
 Table 61. Travere Therapeutics Revenue in APOL1 Mediated Kidney Disease Business (2020-2025) & (US$ Million)
 Table 62. Travere Therapeutics Recent Development
 Table 63. ChemoCentryx Company Details
 Table 64. ChemoCentryx Business Overview
 Table 65. ChemoCentryx APOL1 Mediated Kidney Disease Product
 Table 66. ChemoCentryx Revenue in APOL1 Mediated Kidney Disease Business (2020-2025) & (US$ Million)
 Table 67. ChemoCentryx Recent Development
 Table 68. ZyVersa Therapeutics Company Details
 Table 69. ZyVersa Therapeutics Business Overview
 Table 70. ZyVersa Therapeutics APOL1 Mediated Kidney Disease Product
 Table 71. ZyVersa Therapeutics Revenue in APOL1 Mediated Kidney Disease Business (2020-2025) & (US$ Million)
 Table 72. ZyVersa Therapeutics Recent Development
 Table 73. GlaxoSmithKline Company Details
 Table 74. GlaxoSmithKline Business Overview
 Table 75. GlaxoSmithKline APOL1 Mediated Kidney Disease Product
 Table 76. GlaxoSmithKline Revenue in APOL1 Mediated Kidney Disease Business (2020-2025) & (US$ Million)
 Table 77. GlaxoSmithKline Recent Development
 Table 78. Novartis Company Details
 Table 79. Novartis Business Overview
 Table 80. Novartis APOL1 Mediated Kidney Disease Product
 Table 81. Novartis Revenue in APOL1 Mediated Kidney Disease Business (2020-2025) & (US$ Million)
 Table 82. Novartis Recent Development
 Table 83. Teva Pharmaceuticals Company Details
 Table 84. Teva Pharmaceuticals Business Overview
 Table 85. Teva Pharmaceuticals APOL1 Mediated Kidney Disease Product
 Table 86. Teva Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2020-2025) & (US$ Million)
 Table 87. Teva Pharmaceuticals Recent Development
 Table 88. Research Programs/Design for This Report
 Table 89. Key Data Information from Secondary Sources
 Table 90. Key Data Information from Primary Sources
 Table 91. Authors List of This Report


List of Figures
 Figure 1. APOL1 Mediated Kidney Disease Picture
 Figure 2. Global APOL1 Mediated Kidney Disease Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global APOL1 Mediated Kidney Disease Market Share by Type: 2024 VS 2031
 Figure 4. Small Molecule Features
 Figure 5. Gene Modification Features
 Figure 6. Nucleic Acid Therapies Features
 Figure 7. Others Features
 Figure 8. Global APOL1 Mediated Kidney Disease Market Size by Application (2020-2031) & (US$ Million)
 Figure 9. Global APOL1 Mediated Kidney Disease Market Share by Application: 2024 VS 2031
 Figure 10. Chronic Kidney Disease Case Studies
 Figure 11. End Stage Kidney Disease Case Studies
 Figure 12. APOL1 Mediated Kidney Disease Report Years Considered
 Figure 13. Global APOL1 Mediated Kidney Disease Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 14. Global APOL1 Mediated Kidney Disease Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global APOL1 Mediated Kidney Disease Market Share by Region: 2024 VS 2031
 Figure 16. Global APOL1 Mediated Kidney Disease Market Share by Players in 2024
 Figure 17. Global Top APOL1 Mediated Kidney Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in APOL1 Mediated Kidney Disease as of 2024)
 Figure 18. The Top 10 and 5 Players Market Share by APOL1 Mediated Kidney Disease Revenue in 2024
 Figure 19. North America APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 20. North America APOL1 Mediated Kidney Disease Market Share by Country (2020-2031)
 Figure 21. United States APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Canada APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe APOL1 Mediated Kidney Disease Market Share by Country (2020-2031)
 Figure 25. Germany APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. France APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. U.K. APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Italy APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Russia APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Nordic Countries APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific APOL1 Mediated Kidney Disease Market Share by Region (2020-2031)
 Figure 33. China APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Japan APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. South Korea APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Southeast Asia APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. India APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Australia APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America APOL1 Mediated Kidney Disease Market Share by Country (2020-2031)
 Figure 41. Mexico APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Brazil APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa APOL1 Mediated Kidney Disease Market Share by Country (2020-2031)
 Figure 45. Turkey APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Saudi Arabia APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. UAE APOL1 Mediated Kidney Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Vertex Pharmaceuticals Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2020-2025)
 Figure 49. Ionis Pharmaceuticals Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2020-2025)
 Figure 50. Travere Therapeutics Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2020-2025)
 Figure 51. ChemoCentryx Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2020-2025)
 Figure 52. ZyVersa Therapeutics Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2020-2025)
 Figure 53. GlaxoSmithKline Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2020-2025)
 Figure 54. Novartis Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2020-2025)
 Figure 55. Teva Pharmaceuticals Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2020-2025)
 Figure 56. Bottom-up and Top-down Approaches for This Report
 Figure 57. Data Triangulation
 Figure 58. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano String

SIMILAR REPORTS

Global Nephro Genetic Testing Market Research Report 2025
Global Renal Therapeutic Market Research Report 2025
Global Bartter Syndrome Treatment Market Research Report 2024
Global Renal Diseases Drug Market Insights Forecast to 2030
Global APO E Gene Test Kit Market Research Report 2025
Global APO E Gene Test Market Research Report 2025
Global Focal Nodular Glomerulosclerosis FSGS Treatment Medicine Market Research Report 2025
Global Apolipoprotein E Genotype Test Kit Market Research Report 2025
Global Bartter Syndrome Drugs Market Research Report 2024
Global End Stage Kidney Disease Market Research Report 2024
Global Focal Glomerular Sclerosis FSGS Treatment Medicine Market Research Report 2025
Kidney Machines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Chronic Kidney Disease Medication Market Research Report 2024
Global End Stage Renal Disease Market Research Report 2024
Renal Biomarkers Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global MUC1 ELISA Kits Market Research Report 2024
Kidney Renal Fibrosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Gene Knockdown Stable Cell Line Service Market Research Report 2024
Sphingosine 1 Receptor Modulators Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Drugs for Alport Syndrome Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Insulin Coolers Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19Z7671
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Ossicular Prostheses Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10V14317
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Defibrillator Accessories Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10O5919
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Septicemia Diagnostic Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-4I19963
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions